Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
2.335
+0.035 (1.52%)
At close: Nov 20, 2026, 4:00 PM EST
2.340
+0.005 (0.21%)
After-hours: Nov 20, 2026, 7:51 PM EST
Alector Revenue
Alector had revenue of $162.87M in the quarter ending September 30, 2026, with 4,895.89% growth. This brings the company's total for the last twelve months to $173.47M, up 151.23% year-over-year. In the year 2025, Alector had annual revenue of $21.05M, down -79.07%. That makes Alector the 18,538th largest company in the world by revenue and 2,963rd in the United States.
Revenue (ttm)
$173.47M
Revenue Growth
+151.23%
P/S Ratio
2.00
Revenue / Employee
$1,684,165
Employees
103
Market Cap
347.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.05M | -79.51M | -79.07% |
| Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | 21.22M | -6.46M | -23.33% |
| Dec 31, 2018 | 27.68M | 23.94M | 641.02% |
| Dec 31, 2017 | 3.74M | 3.32M | 797.84% |
| Dec 31, 2016 | 416.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 274.88M |
| Puma Biotechnology | 231.83M |
| C4 Therapeutics | 32.28M |
| Prelude Therapeutics | 21.57M |
| YD Bio | 1.24M |
| Inovio Pharmaceuticals | 298.90K |
| Lyell Immunopharma | 15.00K |
ALEC News
- 9 days ago - Alector initiated with an Overweight at Wells Fargo - TheFly
- 16 days ago - Alector reports Q3 EPS $1.11, consensus 6c - TheFly
- 16 days ago - Alector Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - Alector Earnings release: Q3 2026 - Filings
- 16 days ago - Alector Quarterly report: Q3 2026 - Filings
- 5 weeks ago - Alector prices 36.6M shares of common stock at $2.05 in underwritten offering - TheFly
- 5 weeks ago - Alector Announces Pricing of Underwritten Offering - GlobeNewsWire
- 5 weeks ago - Alector price target raised to $8 from $5 at H.C. Wainwright - TheFly